1. Home
  2. XPEL vs TNDM Comparison

XPEL vs TNDM Comparison

Compare XPEL & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPEL Inc.

XPEL

XPEL Inc.

HOLD

Current Price

$46.71

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$20.27

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPEL
TNDM
Founded
1999
2006
Country
United States
United States
Employees
1337
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
XPEL
TNDM
Price
$46.71
$20.27
Analyst Decision
Strong Buy
Buy
Analyst Count
1
19
Target Price
$56.00
$28.00
AVG Volume (30 Days)
232.9K
1.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
12.12
N/A
EPS
1.85
N/A
Revenue
$476,200,000.00
$1,014,736,000.00
Revenue This Year
$12.64
$8.11
Revenue Next Year
$11.98
$11.85
P/E Ratio
$25.26
N/A
Revenue Growth
13.27
7.93
52 Week Low
$26.96
$10.00
52 Week High
$55.91
$29.65

Technical Indicators

Market Signals
Indicator
XPEL
TNDM
Relative Strength Index (RSI) 59.28 47.04
Support Level $31.55 $19.70
Resistance Level $55.36 $21.68
Average True Range (ATR) 1.60 1.18
MACD 0.15 0.14
Stochastic Oscillator 49.91 55.97

Price Performance

Historical Comparison
XPEL
TNDM

About XPEL XPEL Inc.

XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: